TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 12845387
Drug: Ginkgo biloba
Normalized name: Ginkgo Biloba
DrugBank: Ginkgo biloba (DB01381)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ginkgo biloba (GB) therapy, 80 mg three times daily
Study: 1458890
Drug: 1 mg
Normalized name: biotin 1 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1 mg gemeprost as a vaginal pessary
Study: 1458890
Drug: Treatment in
Normalized name: Other agents for local oral treatment in ATC
Approvals — FDA: no, EMA: no, PMDA: no
Description: Treatment in the sitting-room
Study: 1458890
Drug: Treatment in
Normalized name: Other agents for local oral treatment in ATC
Approvals — FDA: no, EMA: no, PMDA: no
Description: Treatment in the ward
Study: 1458890
Drug: Overall satisfaction
Approvals — FDA: no, EMA: no, PMDA: no
Description: Overall satisfaction with method of treatment
Study: 1458890
Drug: Preference to
Normalized name: Wong To Yick
Approvals — FDA: no, EMA: no, PMDA: no
Description: Preference to stay in hospital after administration of prostaglandin
Study: 29633139
Drug: Response by
Normalized name: By Ache
Approvals — FDA: no, EMA: no, PMDA: no
Description: Response by method of PRO administration
Study: 27511452
Drug: Testosterone (T)
Normalized name: Testosterone
DrugBank: (1,2,6,7-3H)Testosterone (DB14093)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Testosterone (T) administration
Study: 23489530
Drug: Insulin resistance
Normalized name: INSULIN
DrugBank: Insulin beef (DB09456)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Insulin resistance (HOMA >1.24)
Study: 23489530
Drug: Insulin resistance
Normalized name: INSULIN
DrugBank: Insulin beef (DB09456)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Insulin resistance (HOMA <1.24)
Study: 16166441
Drug: 2-methoxyestradiol 1,200
Approvals — FDA: no, EMA: no, PMDA: no
Description: 2-methoxyestradiol 1,200 mg/d
Study: 16166441
Drug: 2-methoxyestradiol 400
Approvals — FDA: no, EMA: no, PMDA: no
Description: 2-methoxyestradiol 400 mg/d
Study: 15709726
Drug: STA-MCA anastomosis
Approvals — FDA: no, EMA: no, PMDA: no
Description: STA-MCA anastomosis combined with best medical therapy
Study: 10588962
Drug: Immediate antiandrogen
Approvals — FDA: no, EMA: no, PMDA: no
Description: Immediate antiandrogen therapy (goserelin or bilateral orchiectomy)
Study: 8759656
Drug: Omeprazole 20
Normalized name: omeprazole 20 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Omeprazole 20 mg b.i.d.
Study: 15298636
Drug: Omeprazole 80
Normalized name: Omeprazole
DrugBank: Omeprazole (DB00338)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Omeprazole 80 mg/day
Study: 30576544
Drug: Netupitant 30
Normalized name: netupitant 300 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Netupitant 30 mg
Study: 26511056
Drug: Bone marrow
Normalized name: bone marrow
Approvals — FDA: no, EMA: no, PMDA: no
Description: Bone marrow derived mononuclear cell (BMMNC) administration
Study: 19678774
Drug: Ginkgo biloba
Normalized name: Ginkgo Biloba
DrugBank: Ginkgo biloba (DB01381)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ginkgo biloba L. tablets (40 mg leaf extracts), taken three times a day from the 16th day of the menstrual cycle to the 5th day of the next cycle.
Study: 17183512
Drug: Control group
Normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control group received conventional treatment (corticosteroid injections, stretching, or no intervention).
Study: 15334379
Drug: Pancreas Tonic
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pancreas Tonic (2 capsules 3 times a day) for 3 months
Study: 9274439
Drug: exemestane 0.5
Approvals — FDA: no, EMA: no, PMDA: no
Description: exemestane 0.5 mg
Study: 9274439
Drug: exemestane 1
Normalized name: Exemestane
DrugBank: Exemestane (DB00990)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: exemestane 1 mg
Study: 9274439
Drug: exemestane 2.5
Approvals — FDA: no, EMA: no, PMDA: no
Description: exemestane 2.5 mg
Study: 9274439
Drug: exemestane 5
Normalized name: Exemestane
DrugBank: Exemestane (DB00990)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: exemestane 5 mg
Study: 9274439
Drug: exemestane (all
Approvals — FDA: no, EMA: no, PMDA: no
Description: exemestane (all doses)
Study: 7686279
Drug: Continuous subcutaneous
Normalized name: Ivy Dry Super Continuous Spray
Approvals — FDA: no, EMA: no, PMDA: no
Description: Continuous subcutaneous infusion (mode A)
Study: 7686279
Drug: Continuous basal
Normalized name: Ivy Dry Super Continuous Spray
Approvals — FDA: no, EMA: no, PMDA: no
Description: Continuous basal rate subcutaneous infusion + PCA (mode B)
Study: 27510536
Drug: Drinking 300
Approvals — FDA: no, EMA: no, PMDA: no
Description: Drinking 300 mL H2O during the 4-hour period
Study: 23175912
Drug: Dance Movement
Normalized name: ethanol
DrugBank: Ethanol (DB00898)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Dance Movement Therapy (DMT), 2 times a week for 4 weeks
Study: 20631559
Drug: Atypical antipsychotic
Approvals — FDA: no, EMA: no, PMDA: no
Description: Atypical antipsychotic agents (especially clozapine) in patients with comorbid psychosis (DD)
Study: 20631559
Drug: Atypical antipsychotic
Approvals — FDA: no, EMA: no, PMDA: no
Description: Atypical antipsychotic agents in patients without comorbid psychosis (SD)
Study: 18202708
Drug: Dorzolamide 2%
Normalized name: Brimonidine Tartrate 0.1%, Dorzolamide 2% Ophthalmic drops, solution
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dorzolamide 2% monotherapy
Study: 18202708
Drug: Timolol 0.50%
Approvals — FDA: no, EMA: no, PMDA: no
Description: Timolol 0.50% monotherapy
Study: 18202708
Drug: Dorzolamide/timolol fixed
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dorzolamide/timolol fixed combination
Study: 10344454
Drug: 400 mg
Normalized name: mesna 400 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 400 mg day(‐1) vitamin E supplementation for 28 days
Study: 31024092
Drug: High dairy
Normalized name: Beano Dairy Defense
Approvals — FDA: no, EMA: no, PMDA: no
Description: High dairy condition (four daily servings of whole milk or full-fat dairy products)
Study: 28118425
Drug: Glutamate injections
Normalized name: glutamate
DrugBank: Leucovorin (DB00650)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Glutamate injections
Study: 28118425
Drug: Glutamate injections
Normalized name: glutamate
DrugBank: Leucovorin (DB00650)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Glutamate injections with 0.5 kg and 1.0 kg pressure
Study: 25501607
Drug: Lipid-based nutritional
Normalized name: guggul lipids
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lipid-based nutritional supplements with added vitamins and minerals (LNS-VM)
Study: 25501607
Drug: Lipid-based nutritional
Normalized name: guggul lipids
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lipid-based nutritional supplements without added vitamins and minerals (LNS)
Study: 24602760
Drug: Maintenance rituximab
Normalized name: Rituximab
DrugBank: Rituximab (DB00073)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Maintenance rituximab (rituximab 375 mg/m² weekly for 4 weeks followed by 12 infusions at 2-month intervals for 2 years)
Study: 24602760
Drug: Rituximab induction
Normalized name: Rituximab
DrugBank: Rituximab (DB00073)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Rituximab induction (rituximab 375 mg/m² weekly for 4 weeks)
Study: 19774308
Drug: Botulinum toxin
Normalized name: Botulinum toxin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Botulinum toxin type A mixed with 2 ml saline
Study: 19774308
Drug: Botulinum toxin
Normalized name: Botulinum toxin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Botulinum toxin type A mixed with 8 ml saline
Study: 11277343
Drug: Hairgain (active
Approvals — FDA: no, EMA: no, PMDA: no
Description: Hairgain (active preparation)
Study: 9533060
Drug: Eprosartan 400
Normalized name: eprosartan 400 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Eprosartan 400 mg alone
Study: 9533060
Drug: Eprosartan 400
Normalized name: eprosartan 400 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Eprosartan 400 mg with ranitidine 150 mg after 3 days of ranitidine 150 mg twice daily
Study: 8029793
Drug: Low molecular
Normalized name: Low molecular weight heparin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Low molecular weight heparin (LMWH) - ardeparin
Study: 8029793
Drug: Low molecular
Normalized name: Low molecular weight heparin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Low molecular weight heparin (LMWH) - 4 different LMWHs
Study: 28693854
Drug: bOPV and
Normalized name: cytarabine and daunorubicin
Approvals — FDA: no, EMA: no, PMDA: no
Description: bOPV and one dose of IPV
Study: 28693854
Drug: bOPV and
Normalized name: cytarabine and daunorubicin
Approvals — FDA: no, EMA: no, PMDA: no
Description: bOPV and two doses of IPV
Study: 25711726
Drug: Diazepam 10.0
Approvals — FDA: no, EMA: no, PMDA: no
Description: Diazepam 10.0 mg
Study: 19653786
Drug: Cocaine (175
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cocaine (175 mg, p.o.; 5 hourly doses; 875 mg/day)
Study: 16442902
Drug: Low-dose warfarin
Normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Low-dose warfarin or placebo
Study: 16442902
Drug: Lovastatin in
Normalized name: Product containing lovastatin in oral dose form (medicinal product form)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lovastatin in low or high doses
Study: 8290902
Drug: Ceftazidime 2
Normalized name: ceftazidime 2000 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ceftazidime 2 g bid
Study: 8360130
Drug: Imipenem/cilastatin 0.5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Imipenem/cilastatin 0.5 g qid
Study: 3098997
Drug: Physical therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Physical therapy thrice weekly (PT3)
Study: 3098997
Drug: Physical therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Physical therapy five times weekly (PT5)
Study: 3098997
Drug: No therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: No therapy (controls)
Study: 31526206
Drug: Cabergoline (1
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cabergoline (1 mg)
Study: 29211123
Drug: External Hexagon
Normalized name: CATHETER,EXTERNAL
Approvals — FDA: no, EMA: no, PMDA: no
Description: External Hexagon (EH) implants
Study: 27353076
Drug: Morse-Taper (MT)
Normalized name: caper berry extract
Approvals — FDA: no, EMA: no, PMDA: no
Description: Morse-Taper (MT) implants
Study: 15486152
Drug: Therapeutic Touch
Normalized name: Moisturel Therapeutic
Approvals — FDA: no, EMA: no, PMDA: no
Description: Therapeutic Touch (20 minutes daily for 7 days)
Study: 15486152
Drug: Shared activity
Normalized name: Activated Charcoal
DrugBank: Activated charcoal (DB09278)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Shared activity with a registered nurse (20 minutes daily for 7 days)
Study: 29882388
Drug: Immunotherapy treatments
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Immunotherapy treatments with various doses (specific dosages not mentioned)
Study: 29882388
Drug: Safe doses
Normalized name: Safe-Guard
Approvals — FDA: no, EMA: no, PMDA: no
Description: Safe doses identified in the first stage of the trial
Study: 24341527
Drug: 0.03 mg
Normalized name: biotin 0.03 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.03 mg MRrhTSH
Study: 24341527
Drug: 0.01 mg
Normalized name: urea 0.01 MG/MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.01 mg MRrhTSH
Study: 24341527
Drug: 0.03 mg
Normalized name: biotin 0.03 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.03 mg MRrhTSH (subgroup with basal (131)I uptake <20%)
Study: 24341527
Drug: 0.01 mg
Normalized name: urea 0.01 MG/MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.01 mg MRrhTSH (subgroup)
Study: 9510281
Drug: Cilostazol (100
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cilostazol (100 mg b.i.d.)
Study: 3394980
Drug: 2 mg
Normalized name: iodine 2 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 2 mg IM butorphanol
Study: 3394980
Drug: 6 mg
Normalized name: boron 6 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 6 mg IM morphine
Study: 31811010
Drug: Internet-based warfarin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Internet-based warfarin anticoagulation management model
Study: 28943074
Drug: Conventional fractionated
Normalized name: LIVER FRACTION
Approvals — FDA: no, EMA: no, PMDA: no
Description: Conventional fractionated radiation therapy (78 Gy in 39 fractions)
Study: 28943074
Drug: Hypofractionated radiation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Hypofractionated radiation therapy (64.6 Gy in 19 fractions)
Study: 23301875
Drug: Coenzyme Q10
Normalized name: Coenzyme Q10
DrugBank: Ubidecarenone (DB09270)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Coenzyme Q10 (400 mg) and selenium (200 μg) supplementation for 12 weeks
Study: 16752942
Drug: ASA 500
Normalized name: ASA 500 MG Oral Tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: ASA 500 mg
Study: 16752942
Drug: ASA +
Normalized name: Aspirin
DrugBank: Acetylsalicylic acid (DB00945)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: ASA + EGb 761 240 mg
Study: 15087629
Drug: Intrathecal analgesia
Normalized name: Analgesic Balm GRX
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intrathecal analgesia (bupivacaine 15 mg, clonidine 75 microg, morphine 0.2 mg)
Study: 15087629
Drug: General anesthesia
Normalized name: Ethers for general anesthesia
Approvals — FDA: no, EMA: no, PMDA: no
Description: General anesthesia supplemented with intravenous fentanyl
Study: 11576197
Drug: rizatriptan ODT
DrugBank: Rizatriptan (DB00953)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: rizatriptan ODT 10-mg
Study: 9767742
Drug: Preoperative erythropoietin
Normalized name: Erythropoietin
DrugBank: Erythropoietin (DB00016)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Preoperative erythropoietin therapy with acute normovolemic hemodilution
Study: 8144779
Drug: Active drug
Normalized name: Capillary active drug
Approvals — FDA: no, EMA: no, PMDA: no
Description: Active drug and Placebo
Study: 8144779
Drug: First drug
Normalized name: Cow first milk
DrugBank: Bos taurus colostrum (DB19249)
Approvals — FDA: no, EMA: no, PMDA: no
Description: First drug tested
Study: 8144779
Drug: Second drug
Normalized name: sodium fluoride
DrugBank: Sodium fluoride (DB09325)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Second drug tested
Study: 2556484
Drug: Alfa LMWH
Normalized name: Darbepoetin Alfa
DrugBank: Darbepoetin alfa (DB00012)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Alfa LMWH 7500 anti-Xa coagulometric units twice daily
Study: 30891605
Drug: Intermittent preventive
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intermittent preventive treatment of malaria in pregnancy (IPTp)
Study: 19843681
Drug: Never used
Approvals — FDA: no, EMA: no, PMDA: no
Description: Never used postmenopausal hormones
Study: 16798698
Drug: Metronidazole 750
Normalized name: metronidazole 750 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Metronidazole 750 mg 3 times daily + S. boulardii 250 mg b.i.d. orally for 10 days
Study: 16798698
Drug: Metronidazole 750
Normalized name: metronidazole 750 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Metronidazole 750 mg 3 times daily + placebo (empty capsules) for 10 days
Study: 15985128
Drug: Bupivacaine wound
Approvals — FDA: no, EMA: no, PMDA: no
Description: Bupivacaine wound infiltration 0.5%; 10 mL, followed by continuous infusion: 10 mg/24 H
Study: 12660513
Drug: Tac triple
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tac triple therapy (n=185)
Study: 10624454
Drug: Vitamin D3
Normalized name: Vitamin D3
DrugBank: Cholecalciferol (DB00169)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Vitamin D3 (440 IU) and Calcium (500 mg, 1250 mg calcium carbonate, Novartis) twice daily
Study: 2172501
Drug: 2',3'-dideoxycytidine (ddC)
DrugBank: Zalcitabine (DB00943)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 2',3'-dideoxycytidine (ddC) at 0.015, 0.02, 0.03, and 0.04 mg/kg, given orally every 6 hours for 8 weeks
Study: 2172501
Drug: Alternating schedule
Normalized name: HERBS/ALTERNATIVE THERAPIES
Approvals — FDA: no, EMA: no, PMDA: no
Description: Alternating schedule of ddC for 1 week followed by AZT (180 mg/m2 every 6 hours) for 3 weeks
Study: 371371
Drug: Beclomethasone dipropionate
Normalized name: Beclomethasone Dipropionate
DrugBank: Beclomethasone dipropionate (DB00394)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Beclomethasone dipropionate aerosol, 50 mcg into each nostril four times a day
Study: 371371
Drug: Placebo aerosol
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo aerosol therapy
Study: 21244240
Drug: Synbiotic product
Normalized name: Synotic Otic Product
Approvals — FDA: no, EMA: no, PMDA: no
Description: Synbiotic product (3 tablets per day, 2.4 × 10^9 colony-forming units/day)
Study: 19591795
Drug: AMA1 vaccine
Normalized name: Pertussis vaccine
DrugBank: Pertussis vaccine (DB15274)
Approvals — FDA: no, EMA: no, PMDA: no
Description: AMA1 vaccine
Study: 17001106
Drug: GH treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: GH treatment at 0.012 mg/kg/day for 24 weeks, followed by individualized dosing for another 24 weeks.
Study: 10699140
Drug: Formula containing
Approvals — FDA: no, EMA: no, PMDA: no
Description: Formula containing 12 mg/L of iron
Study: 10699140
Drug: Formula containing
Approvals — FDA: no, EMA: no, PMDA: no
Description: Formula containing 0.9 mg/L of iron
Study: 8268277
Drug: Other hepatotoxic
Normalized name: Ether
DrugBank: Diethyl ether (DB13598)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Other hepatotoxic drugs
Study: 8268277
Drug: Concomitant exposure
Normalized name: Bacillus anthracis strain V770-NP1-R antigens
DrugBank: Anthrax vaccine (DB11003)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Concomitant exposure to NSAIDs and other hepatotoxic drugs
Study: 3979013
Drug: Deactivation of
Normalized name: OIL OF CAMPHOR
Approvals — FDA: no, EMA: no, PMDA: no
Description: Deactivation of cardiopulmonary receptors
Study: 3979013
Drug: Stimulation of
Approvals — FDA: no, EMA: no, PMDA: no
Description: Stimulation of cardiopulmonary receptors
Study: 29703007
Drug: 3 L PEG
Normalized name: Peg/L-asparaginase
DrugBank: Pegaspargase (DB00059)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 3 L PEG alone
Study: 29703007
Drug: 2 L PEG
Normalized name: Peg/L-asparaginase
DrugBank: Pegaspargase (DB00059)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 2 L PEG plus 30 mL castor oil
Study: 29703007
Drug: 1 L PEG,
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1 L PEG, 30 mL castor oil and 5 g ascorbic acid
Study: 9551706
Drug: Erythromycin 500
Normalized name: erythromycin 500 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Erythromycin 500 mg t.i.d. pre- and co-treatment with cerivastatin 300 microg
Study: 3046554
Drug: 5 mg
Normalized name: talc 25 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 5 mg of fluphenazine decanoate biweekly
Study: 3046554
Drug: 25 mg
Normalized name: talc 25 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 25 mg of fluphenazine decanoate biweekly
Study: 3046554
Drug: Conventional dose
Approvals — FDA: no, EMA: no, PMDA: no
Description: Conventional dose of fluphenazine
Study: 18079068
Drug: Disulfiram-Naltrexone combination
Normalized name: Disulfiram
DrugBank: Disulfiram (DB00822)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Disulfiram-Naltrexone combination
Study: 12743557
Drug: Itraconazole 400
Normalized name: Itraconazole
DrugBank: Itraconazole (DB01167)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Itraconazole 400 mg per day for 16 weeks
Study: 10560780
Drug: Men currently
Approvals — FDA: no, EMA: no, PMDA: no
Description: Men currently using illicit drugs
Study: 10560780
Drug: Men currently
Approvals — FDA: no, EMA: no, PMDA: no
Description: Men currently taking HBP medication
Study: 26173911
Drug: Inpatient prostaglandin
Normalized name: Impatiens irvingii whole extract
Approvals — FDA: no, EMA: no, PMDA: no
Description: Inpatient prostaglandin gel (IPG)
Study: 21945130
Drug: Buprenorphine transdermal
Normalized name: Buprenorphine Transdermal System
DrugBank: Buprenorphine (DB00921)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Buprenorphine transdermal system (BTDS) 10 or 20 mcg/hour
Study: 17061223
Drug: Topical anesthesia
Normalized name: Gelato Anesthetic
Approvals — FDA: no, EMA: no, PMDA: no
Description: Topical anesthesia (lidocaine 4%)
Study: 11035828
Drug: Behavioral intervention
Normalized name: hydroquinone
DrugBank: Hydroquinone (DB09526)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Behavioral intervention (behavior therapy)
Study: 6498565
Drug: IV lidocaine
Normalized name: Lidocaine
DrugBank: Lidocaine (DB00281)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: IV lidocaine 1.5 mg X kg‐1
Study: 6498565
Drug: Ten per
Normalized name: TEN
DrugBank: Pentaerythritol tetranitrate (DB06154)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ten per cent lidocaine nasal spray (30 mg in each nostril)
Study: 6498565
Drug: 0.25 per
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.25 per cent phenylephrine nasal spray (0.2 mg in each nostril) (Group C)
Study: 31987122
Drug: 10 capsules/day
Approvals — FDA: no, EMA: no, PMDA: no
Description: 10 capsules/day for four weeks
Study: 31987122
Drug: 400 mL/day
Approvals — FDA: no, EMA: no, PMDA: no
Description: 400 mL/day of a nutritional drink with the same dose of n‐3 LC PUFA
Study: 24344215
Drug: Control -
Normalized name: HISTAMINE 6 mg in 1 mL PERCUTANEOUS INJECTION [Positive Skin Test Control - Histamine]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control - standard treatment
Study: 20695288
Drug: 20% picaridin
Approvals — FDA: no, EMA: no, PMDA: no
Description: 20% picaridin spray
Study: 20695288
Drug: 20% IR3535
Approvals — FDA: no, EMA: no, PMDA: no
Description: 20% IR3535 spray
Study: 20695288
Drug: 20% picaridin
Approvals — FDA: no, EMA: no, PMDA: no
Description: 20% picaridin lotion
Study: 20695288
Drug: 10% IR3535
Approvals — FDA: no, EMA: no, PMDA: no
Description: 10% IR3535 lotion
Study: 20695288
Drug: 33% DEET
Approvals — FDA: no, EMA: no, PMDA: no
Description: 33% DEET cream
Study: 9148172
Drug: Foreign levodopa
Normalized name: Levodopa
DrugBank: Levodopa (DB01235)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Foreign levodopa preparation combined with carbidopa (25/250)
Study: 9148172
Drug: Polish levodopa
Normalized name: Levodopa
DrugBank: Levodopa (DB01235)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Polish levodopa preparation combined with carbidopa (25/250)
Study: 1921737
Drug: 1 mg
Normalized name: biotin 1 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1 mg 17 beta‐oestradiol (E2)
Study: 1921737
Drug: 2.5 mg
Normalized name: biotin 2.5 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 2.5 mg Org OD 14
Study: 6619028
Drug: Intravenous azlocillin
Normalized name: azlocillin
DrugBank: Azlocillin (DB01061)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Intravenous azlocillin at 6 g/day in three divided doses
Study: 6619028
Drug: Intravenous ticarcillin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous ticarcillin at 8 g/day in four divided doses
Study: 17667476
Drug: Risperidone (0.5-6.0
Approvals — FDA: no, EMA: no, PMDA: no
Description: Risperidone (0.5-6.0 mg/day)
Study: 17667476
Drug: Molindone (10-140
Approvals — FDA: no, EMA: no, PMDA: no
Description: Molindone (10-140 mg/day)
Study: 11258785
Drug: Piperacillin/tazobactam (P/T)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Piperacillin/tazobactam (P/T) 4.5 g i.v. every 6 hours